Drug intelligence / Profile preview

LD18505

Development stage: Preclinical
Lead developer: Shanghai Leado Pharmatech
Modality: Small Molecules

Overview

LD18505 is a preclinical-stage small molecule candidate being developed by Shanghai Leado Pharma (Leado Pharma) for the treatment of depression. As of 2024, the specific biological target and mechanism of action remain undisclosed by the developer, although the company's core expertise lies in the discovery of ion channel-targeted therapeutics. The program is currently undergoing preclinical studies to evaluate its safety and efficacy for potential clinical advancement in depressive disorders.

Other names: LD18505LD-18505LD 18505

Targets

SMARCB1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1)

Beyond the preview

Go deeper on LD18505.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LD18505.

Explore the full profile